Calliotx
Seattle, US · Founded 2025 · 20 employees on LinkedIn · 5 known investors
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment. The company's lead program is a dual-payload HER2-targeted ADC designed to deliver drug combinations to tumor cells.
Founders & leadership
Calliotx was founded in 2025 by Piers Ingram and Jerome Boyd-Kirkup.
PI
Piers IngramPresident, Co-Founder
JB
Jerome Boyd-KirkupChief Scientific Officer, Co-Founder
ZH
Zachary HornbyChief Executive Officer
Investors · 5
In the news
Frequently asked questions
- What does Calliotx do?
- Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment. The company's lead program is a dual-payload HER2-targeted ADC designed to deliver drug combinations to tumor cells.
- Who founded Calliotx?
- Calliotx was founded by Piers Ingram, Jerome Boyd-Kirkup in 2025.
- Who are Calliotx's investors?
- Calliotx's investors include Novo Holdings, Omega Funds, Frazier Life Sciences, Jeito Capital, Norwest Venture Partners.
- Where is Calliotx headquartered?
- Calliotx is headquartered in Seattle, US.